New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): Focus on cardiovascular and neurological diseases

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 734-742

  Mascolo, A ^a   Sessa, M ^a   Scavone, C ^a   De Angelis, A ^a   Vitale, C ^b   Berrino, L ^a   Rossi, F ^a   Rosano, G ^b,c   Capuano, A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin; Coronary artery disease; Heart failure; Neurological diseases; Pharmacology; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II [3-8]; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; HORMONE RECEPTOR STIMULATING AGENT; MINERALOCORTICOID ANTAGONIST; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; UNCLASSIFIED DRUG; ALDOSTERONE;

ALZHEIMER DISEASE; ANXIETY DISORDER; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BRAIN FUNCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; ANIMAL; BRAIN; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; NERVOUS SYSTEM DISEASES; PHYSIOLOGY;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRAIN; CARDIOVASCULAR DISEASES; HUMANS; NERVOUS SYSTEM DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 85003839013     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.069     Document Type: Review

References (109)

1. [1] Ferrario, C.M., The renin–angiotensin system: importance in physiology and pathology. J. Cardiovasc. Pharmacol. 15:Suppl 3 (1990), S1–S5.
2. [2] Rossi, F., Mascolo, A., Mollace, V., The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure. Int. J. Cardiol. 226 (2017), 121–125.
3. [3] Phillips, M.I., de Oliveira, E.M., Brain renin angiotensin in disease. J. Mol. Med. (Berl). 86 (2008), 715–722.
4. [4] Labandeira-García, J.L., Garrido-Gil, P., Rodriguez-Pallares, J., Valenzuela, R., Borrajo, A., Rodríguez-Perez, A.I., Brain renin–angiotensin system and dopaminergic cell vulnerability. Front. Neuroanat., 8, 2014, 67.
5. [5] Mollace, V., Gliozzi, M., Capuano, A., Rossi, F., Modulation of RAAS-natriuretic peptides in the treatment of HF: old guys and newcomers. Int. J. Cardiol. 226 (2017), 126–131.
6. [6] Romero, C.A., Orias, M., Weir, M.R., Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11 (2015), 242–252.
7. [7] Nguyen, G., Renin/prorenin receptors. Kidney Int. 69 (2006), 1503–1506.
8. [8] Schefe, J.H., Menk, M., Reinemund, J., Effertz, K., Hobbs, R.M., Pandolfi, P.P., et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ. Res. 99 (2006), 1355–1366.
9. [9] Unger, T., The role of the renin–angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 89 (2002), 3A–9A.
10. [10] Hargovan, M., Ferro, A., Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc. Dis., 3, 2014.
11. [11] Chaki, S., Inagami, T., Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem. Biophys. Res. Commun. 182 (1992), 388–394.
12. [12] Karamyan, V.T., Arsenault, J., Escher, E., Speth, R.C., Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain. Endocrine 37 (2010), 442–448.
13. [13] Ferreira, A.J., Santos, R.A.S., Bradford, C.N., Mecca, A.P., Sumners, C., Katovich, M.J., et al. Therapeutic implications of the vasoprotective axis of the renin–angiotensin system in cardiovascular diseases. Hypertension 55 (2010), 207–213.
14. [14] Fraga-Silva, R.A., Pinheiro, S.V., Gonçalves, A.C., Alenina, N., Bader, M., Santos, R.A., The antithrombotic effect of angiotensin-(1–7) involves mas-mediated NO release from platelets. Mol. Med. 14 (2008), 28–35.
15. [15] Dias-Peixoto, M.F., Santos, R.A., Gomes, E.R., Alves, M.N., Almeida, P.W., Greco, L., et al. Molecular mechanisms involved in the angiotensin-(1–7)/Mas signaling pathway in cardiomyocytes. Hypertension 52 (2008), 542–548.
16. [16] da Silveira, K.D., Coelho, F.M., Vieira, A.T., Sachs, D., Barroso, L.C., Costa, V.V., et al. Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis. J. Immunol. 185 (2010), 5569–5576.
17. [17] Chappell, M.C., Marshall, A.C., Alzayadneh, E.M., Shaltout, H.A., Diz, D.I., Update on the angiotensin converting enzyme 2-angiotensin (1–7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front. Endocrinol. (Lausanne), 4, 2014, 201.
18. [18] von Lueder, T.G., Atar, D., Krum, H., Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol. Ther. 144 (2014), 41–49.
19. [19] Gao, J., Marc, Y., Iturrioz, X., Leroux, V., Balavoine, F., Llorens-Cortes, C., A new strategy for treating hypertension by blocking the activity of the brain renin–angiotensin system with aminopeptidase A inhibitors. Clin. Sci. 127 (2014), 135–148.
20. [20] Chai, S.Y., Fernando, R., Peck, G., Ye, S.Y., Mendelsohn, F.A., Jenkins, T.A., et al. The angiotensin IV/AT4 receptor. Cell. Mol. Life Sci. 61 (2004), 2728–2737.
21. [21] Kovács, G.L., De Wied, D., Peptidergic modulation of learning and memory processes. Pharmacol. Rev. 46 (1994), 269–291.
22. [22] Gülpinar, M.A., Yegen, B.C., The physiology of learning and memory: role of peptides and stress. Curr. Protein Pept. Sci. 5 (2004), 457–473.
23. [23] Einstein, E.B., Patterson, C.A., Hon, B.J., Regan, K.A., Reddi, J., Melnikoff, D.E., et al. Somatostatin signaling in neuronal cilia is critical for object recognition memory. J. Neurosci. 30 (2010), 4306–4314.
24. [24] Unger, T., Paulis, L., Sica, D.A., Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches. Eur. Heart J. 32 (2011), 2739–2747.
25. [25] Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728 (18 p following 728).
26. [26] Oudit, G.Y., Liu, G.C., Zhong, J., Basu, R., Chow, F.L., Zhou, J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59 (2010), 529–538.
27. [27] Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52 (2013), 783–792.
28. [28] Singh, Y., Singh, K., Sharma, P.L., Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. Mol. Cell. Biochem. 373 (2013), 189–194.
29. [29] Bertagnolli, M., Casali, K.R., De Sousa, F.B., Rigatto, K., Becker, L., Santos, S.H., et al. An orally active angiotensin-(1–7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats. Peptides 51 (2014), 65–73.
30. [30] El-Hashim, A.Z., Renno, W.M., Raghupathy, R., Abduo, H.T., Akhtar, S., Benter, I.F., Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways. Br. J. Pharmacol. 166 (2012), 1964–1976.
31. [31] Rehman, A., Leibowitz, A., Yamamoto, N., Rautureau, Y., Paradis, P., Schiffrin, E.L., Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59 (2012), 291–299.
32. [32] Paulis, L., Becker, S.T., Lucht, K., Schwengel, K., Slavic, S., Kaschina, E., Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 59 (2012), 485–492.
33. [33] Ali, Q., Patel, S., Hussain, T., Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats. Am. J. Physiol. Renal Physiol. 308 (2015), F1379–F1385.
34. [34] Matavelli, L.C., Zatz, R., Siragy, H.M., A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes. J. Cardiovasc. Pharmacol. 65 (2015), 371–376.
35. [35] Capuano, A., Scavone, C., Vitale, C., Sportiello, L., Rossi, F., Rosano, G.M., et al. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int. J. Cardiol. 200 (2015), 15–19.
36. [36] Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34 (2013), 2453–2463.
37. [37] Nariai, T., Fujita, K., Mori, M., Katayama, S., Hori, S., Matsui, K., SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J. Cardiovasc. Pharmacol. 59 (2012), 458–464.
38. [38] Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiss, U., et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 285 (2010), 29932–29940.
39. [39] Kolkhof, P., Nowack, C., Eitner, F., Nonsteroidal antagonists of the mineralocorticoid receptor. Curr. Opin. Nephrol. Hypertens. 24 (2015), 417–424.
40. [40] Zimmer, C., Hafner, M., Zender, M., Ammann, D., Hartmann, R.W., Vock, C.A., N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett. 21 (2011), 186–190.
41. [41] Pandey, R., Quan, W.Y., Hong, F., Jie, S.L., Vaccine for hypertension: modulating the renin–angiotensin system. Int. J. Cardiol. 134 (2009), 160–168.
42. [42] Tissot, A.C., Maurer, P., Nussberger, J., Sabat, R., Pfister, T., Ignatenko, S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (London, England) 371 (2008), 821–827.
43. [43] McMurray, J.J.V., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371 (2014), 993–1004.
44. [44] Baltatu, O., Silva, J.A.J., Ganten, D., Bader, M., The brain renin–angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 35 (2000), 409–412.
45. [45] Llorens-Cortes, C., Mendelsohn, F.A., Organisation and functional role of the brain angiotensin system. J. Renin-Angiotensin-Aldosterone Syst. 3:Suppl 1 (2002), S39–S48.
46. [46] Arnold, A.C., Sakima, A., Kasper, S.O., Vinsant, S., Garcia-Espinosa, M.A., Diz, D.I., The brain renin–angiotensin system and cardiovascular responses to stress: insights from transgenic rats with low brain angiotensinogen. J. Appl. Physiol. 113 (2012), 1929–1936.
47. [47] Saavedra, J.M., Benicky, J., Zhou, J., Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell. Mol. Neurobiol. 26 (2006), 1099–1111.
48. [48] Phillips, M.I., Felix, D., Specific angiotensin II receptive neurons in the cat subfornical organ. Brain Res. 109 (1976), 531–540.
49. [49] Phillips, M.I., Mann, J.F., Haebara, H., Hoffman, W.E., Dietz, R., Schelling, P., et al. Lowering of hypertension by central saralasin in the absence of plasma renin. Nature 270 (1977), 445–447.
50. [50] Berecek, K.H., Nagahama, S., Oparil, S., Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat. J. Hypertens. Suppl. 2 (1984), S63–S66.
51. [51] Kubo, T., Ikezawa, A., Kambe, T., Hagiwara, Y., Fukumori, R., Renin antisense injected intraventricularly decreases blood pressure in spontaneously hypertensive rats. Brain Res. Bull. 56 (2001), 23–28.
52. [52] Bertram, D., Coote, J.H., Inhibitory effects of angiotensin II on barosensitive rostral ventrolateral medulla neurons of the rat. Clin. Exp. Pharmacol. Physiol. 28 (2001), 1112–1114.
53. [53] Bunag, R.D., Eriksson, L., Tanabe, S., Baroreceptor reflex enhancement by chronic intracerebroventricular infusion of enalapril in normotensive rats. Hypertension 15 (1990), 284–290.
54. [54] Abdulla, M.H., Johns, E.J., Nitric oxide impacts on angiotensin AT2 receptor modulation of high-pressure baroreflex control of renal sympathetic nerve activity in anaesthetized rats. Acta Physiol. (Oxf). 210 (2014), 832–844.
55. [55] Li, W., Peng, H., Cao, T., Sato, R., McDaniels, S.J., Kobori, H., et al. Brain-targeted (pro)renin receptor knockdown attenuates angiotensin II-dependent hypertension. Hypertension 59 (2012), 1188–1194.
56. [56] Shan, Z., Shi, P., Cuadra, A.E., Dong, Y., Lamont, G.J., Li, Q., et al. Involvement of the brain (pro)renin receptor in cardiovascular homeostasis. Circ. Res. 107 (2010), 934–938.
57. [57] Li, W., Sullivan, M.N., Zhang, S., Worker, C.J., Xiong, Z., Speth, R.C., et al. Intracerebroventricular infusion of the (pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension. Hypertension 65 (2015), 352–361.
58. [58] Bourassa, E.A., Fang, X., Li, X., Sved, A.F., Speth, R.C., AT₁ angiotensin II receptor and novel non-AT₁, non-AT₂ angiotensin II/III binding site in brainstem cardiovascular regulatory centers of the spontaneously hypertensive rat. Brain Res. 1359 (2010), 98–106.
59. [59] Xue, B., Zhang, Z., Johnson, R.F., Guo, F., Hay, M., Johnson, A.K., Central endogenous angiotensin-(1–7) protects against aldosterone/NaCl-induced hypertension in female rats. Am. J. Physiol. Heart Circ. Physiol. 305 (2013), H699–H705.
60. [60] Sriramula, S., Xia, H., Xu, P., Lazartigues, E., Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. Hypertension 65 (2015), 577–586.
61. [61] Leenen, F.H., Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension. Am. J. Hypertens. 27 (2014), 1024–1032.
62. [62] Yu, Y., Wei, S.G., Zhang, Z.H., Gomez-Sanchez, E., Weiss, R.M., Felder, R.B., Does aldosterone upregulate the brain renin–angiotensin system in rats with heart failure?. Hypertension 51 (2008), 727–733.
63. [63] Zhang, Z.H., Yu, Y., Kang, Y.M., Wei, S.G., Felder, R.B., Aldosterone acts centrally to increase brain renin–angiotensin system activity and oxidative stress in normal rats. Am. J. Physiol. Heart Circ. Physiol. 294 (2008), H1067–H1074.
64. [64] Tsuda, K., Renin–angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension. Int. J. Hypertens., 2012, 2012, 474870.
65. [65] Mayorov, D.N., Brain superoxide as a key regulator of the cardiovascular response to emotional stress in rabbits. Exp. Physiol. 92 (2007), 471–479.
66. [66] Nautiyal, M., Katakam, P.V., Busija, D.W., Gallagher, P.E., Tallant, E.A., Chappell, M.C., et al. Differences in oxidative stress status and expression of MKP-1 in dorsal medulla of transgenic rats with altered brain renin–angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303 (2012), R799–R806.
67. [67] Araujo, I.G., Trindade, D.C., Mecawi, A.S., Sonoda-Cortes, R., Werneck-de-Castro, J.P., Costa-E-Sousa, R.H., et al. Inhibition of brain renin–angiotensin system improves diastolic cardiac function following myocardial infarction in rats. Clin. Exp. Pharmacol. Physiol. 36 (2009), 803–809.
68. [68] Chen, S., Li, G., Zhang, W., Wang, J., Sigmund, C.D., Olson, J.E., et al. Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297 (2009), R1526–R1531.
69. [69] Xia, H., Lazartigues, E., Angiotensin-converting enzyme 2 in the brain: properties and future directions. J. Neurochem. 107 (2008), 1482–1494.
70. [70] Dupont, A.G., Brouwers, S., Brain angiotensin peptides regulate sympathetic tone and blood pressure. J. Hypertens. 28 (2010), 1599–1610.
71. [71] Francis, J., Wei, S.G., Weiss, R.M., Felder, R.B., Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure. Am. J. Physiol. Heart Circ. Physiol. 287 (2004), H2138–H2146.
72. [72] Huang, B.S., Ahmad, M., Tan, J., Leenen, F.H., Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. J. Mol. Cell. Cardiol. 43 (2007), 479–486.
73. [73] Isegawa, K., Hirooka, Y., Katsuki, M., Kishi, T., Sunagawa, K., Angiotensin II type 1 receptor expression in astrocytes is upregulated leading to increased mortality in mice with myocardial infarction-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 307 (2014), H1448–H1455.
74. [74] Itoh, H., Nakao, K., Yamada, T., Morii, N., Shiono, S., Sugawara, A., et al. Brain renin–angiotensin. Central control of secretion of atrial natriuretic factor from the heart. Hypertension 11 (1988), I57–I61.
75. [75] Ohrui, T., Matsui, T., Yamaya, M., Arai, H., Ebihara, S., Maruyama, M., Sasaki, H., Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J. Am. Geriatr. Soc. 52 (2004), 649–650.
76. [76] Ohrui, T., Tomita, N., Sato-Nakagawa, T., Matsui, T., Maruyama, M., Niwa, K., et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63 (2004), 1324–1325.
77. [77] Bild, W., Hritcu, L., Stefanescu, C., Ciobica, A., Inhibition of central angiotensin II enhances memory function and reduces oxidative stress status in rat hippocampus. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 43 (2013), 79–88.
78. [78] Kehoe, P.G., Wilcock, G.K., Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol. 6 (2007), 373–378.
79. [79] AbdAlla, S., Langer, A., Fu, X., Quitterer, U., ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. Int. J. Mol. Sci. 14 (2013), 16917–16942.
80. [80] Dong, Y.F., Kataoka, K., Toyama, K., Sueta, D., Koibuchi, N., Yamamoto, E., et al. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension 58 (2011), 635–642.
81. [81] Chai, S.Y., Yeatman, H.R., Parker, M.W., Ascher, D.B., Thompson, P.E., Mulvey, H.T., et al. Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neurosci., 9(Suppl 2), 2008, S14.
82. [82] Fernando, R.N., Albiston, A.L., Chai, S.Y., The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus—potential role in modulation of glucose uptake in neurones?. Eur. J. Neurosci. 28 (2008), 588–598.
83. [83] Vanderheyden, P.M., From angiotensin IV binding site to AT4 receptor. Mol. Cell. Endocrinol. 302 (2009), 159–166.
84. [84] Braszko, J.J., D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6 Ang IV. Physiol. Behav. 88 (2006), 152–159.
85. [85] Braszko, J.J., Dopamine D4 receptor antagonist L745,870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe(6)-Ang IV in rats. Eur. Neuropsychopharmacol. 19 (2009), 85–91.
86. [86] Lee, J., Chai, S.Y., Mendelsohn, F.A., Morris, M.J., Allen, A.M., Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 40 (2001), 618–623.
87. [87] Olson, M.L., Cero, I.J., Intrahippocampal norleucine(1)-angiotensin IV mitigates scopolamine-induced spatial working memory deficits. Peptides 31 (2010), 2209–2215.
88. [88] Hellner, K., Walther, T., Schubert, M., Albrecht, D., Angiotensin-(1–7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol. Cell. Neurosci. 29 (2005), 427–435.
89. [89] Jiang, T., Zhang, Y.D., Zhou, J.S., Zhu, X.C., Tian, Y.Y., Zhao, H.D., et al. Angiotensin-(1–7) is reduced and inversely correlates with tau hyperphosphorylation in animal models of Alzheimer's disease. Mol. Neurobiol. 53 (2016), 2489–2497.
90. [90] Labandeira-Garcia, J.L., Rodriguez-Pallares, J., Dominguez-Meijide, A., Valenzuela, R., Villar-Cheda, B., Rodriguez-Perez, A.I., Dopamine–angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov. Disord. 28 (2013), 1337–1342.
91. [91] Sonsalla, P.K., Coleman, C., Wong, L.Y., Harris, S.L., Richardson, J.R., Gadad, B.S., et al. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp. Neurol. 250 (2013), 376–383.
92. [92] Gard, P.R., The brain renin–angiotensin system: a target for novel antidepressants and anxiolytics. Drug Dev. Res. 65 (2005), 270–277.
93. [93] Wang, L., de Kloet, A.D., Pati, D., Hiller, H., Smith, J.A., Pioquinto, D.J., et al. Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors. Neuropharmacology 105 (2016), 114–123.
94. [94] de Gois Queiroz, A.I., Medeiros, C.D., Ribeiro, B.M., de Lucena, D.F., Macedo, D.S., Angiotensin receptor blockers for bipolar disorder. Med. Hypotheses 80 (2013), 259–263.
95. [95] Paz, M.C., Assis, M.A., Cabrera, R.J., Cancela, L.M., Bregonzio, C., The AT₁ angiotensin II receptor blockade attenuates the development of amphetamine-induced behavioral sensitization in a two-injection protocol. Synapse 65 (2011), 505–512.
96. [96] Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., et al. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect. Disord. 141 (2012), 1–10.
97. [97] Kishi, T., Hirooka, Y., Sunagawa, K., Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. J. Cardiol. 60 (2012), 489–494.
98. [98] Germain, L., Chouinard, G., Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol. Psychiatry 25 (1989), 489–493.
99. [99] Gard, N., Mycroft, P.R., Reduction of angiotensin II-induced drinking in rats by 21 hour pretreatment with desipramine. J. Pharm. Pharmacol., 43, 1991, 1.
100. [100] Gard, P.R., Mandy, A., Whiting, J.M., Nickels, D.P., Meakin, A.J., Reduction of responses to angiotensin II by antidepressant drugs. Eur. J. Pharmacol. 264 (1994), 295–300.
101. [101] Murck, H., Schussler, P., Steiger, A., Renin–angiotensin–aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry 45 (2012), 83–95.
102. [102] Fournie-Zaluski, M.C., Fassot, C., Valentin, B., Djordjijevic, D., Reaux-Le Goazigo, A., Corvol, P., et al. Brain renin–angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 7775–7780.
103. [103] Marc, Y., Gao, J., Balavoine, F., Michaud, A., Roques, B.P., Llorens-Cortes, C., Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension 60 (2012), 411–418.
104. [104] Huang, B.S., Ahmad, M., White, R.A., Marc, Y., Llorens-Cortes, C., Leenen, F.H., Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction. Cardiovasc. Res. 97 (2013), 424–431.
105. [105] Balavoine, F., Azizi, M., Bergerot, D., De Mota, N., Patouret, R., Roques, B.P., et al. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. Clin. Pharmacokinet. 53 (2014), 385–395.
106. [106] US National Library of Medicine. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02322450?term=QGC001&rank=3, (2015).
107. [107] Wright, J.W., Kawas, L.H., Harding, J.W., The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog. Neurobiol. 125 (2015), 26–46.
108. [108] Benoist, C.C., Wright, J.W., Zhu, M., Appleyard, S.M., Wayman, G.A., Harding, J.W., Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J. Pharmacol. Exp. Ther. 339 (2011), 35–44.
109. [109] McCoy, A.T., Benoist, C.C., Wright, J.W., Kawas, L.H., Bule-Ghogare, J.M., Zhu, M., et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J. Pharmacol. Exp. Ther. 344 (2013), 141–154.